Subscribe

Drug Updates

The Leucovorin Shortage: A Tangled Web of Similar Isomers and Huge Cost Differences
By Laura R. Bobolts, PharmD, BCOP; Valerie Fishman, RN; Marc Fishman, MD; William Hrushesky, MD; Dinah Huff, MD; Jurgen Kogler, MD; William Shimp, MD
Drug Updates
July 2013, Vol 4, No 6
After being in short supply since 2008, leucovorin, an analog of folic acid, is now more readily available, and the economics of US cancer care are about to have a bit of a reprieve.
Read Article
Ponatinib: New Option for the Treatment of Adults with CML or Ph+ ALL that Is Resistant or Intolerant to Previous Therapy with Tyrosine Kinase Inhibitors
By Lynne Lederman, PhD, Medical Writer
Drug Updates
February 2013, Vol 4, No 2
On December 14, 2012, the US Food and Drug Administration (FDA) granted accelerated approval to ponatinib (Iclusig; ARIAD Pharmaceuticals) based on the results from a phase 2 clinical trial.
Read Article
Ziv-Aflibercept: A New Option for the Treatment of Patients with Metastatic Colorectal Cancer Resistant to or Progressing After an Oxaliplatin-Containing Regimen
By Lynne Lederman, PhD, Medical Writer
Drug Updates
January 2013, Vol 4, No 1
On August 3, 2012, the US Food and Drug Administration (FDA) approved ziv-aflibercept (Zaltrap) for use in combination with a FOLFIRI chemotherapy regimen to treat adults with mCRC that is resistant to or has progressed after an oxaliplatin-containing regimen.
Read Article
Pertuzumab a New Therapeutic Option for Patients with HER2-Positive Metastatic Breast Cancer
By Alice Goodman
Drug Updates
October 2012, Vol 3, No 7
Pertuzumab, the third HER2-targeted agent with a unique mechanism of action, was approved in July 2012 by the FDA for the treatment of metastatic HER2-positive breast cancer in combination with trastuzumab plus docetaxel.
Read Article
Carfilzomib a New Option for the Treatment of Patients with Relapsed, Refractory Multiple Myeloma Previously Treated with Bortezomib and an Immunomodulatory Agent
By Lynne Lederman, PhD, Medical Writer
Drug Updates
September 2012, Vol 3, No 6

Multiple myeloma (MM), a clonal malignancy of plasma cells, is responsible for 10% to 15% of all hematologic malignancies and for 20% of deaths resulting from hematologic cancers.1,2 In most patients, MM evolves from monoclonal gammopathy of undetermined significance (MGUS), an asymptomatic plasma-cell disorder.

Read Article
Economic Implications of Biosimilars in Oncology
By Caroline Helwick
Drug Updates, Biosimilars
December 2011, Vol 2, No 7
Alternative versions of biologic agents—biosimilars—will be coming soon to a formulary near you. In the meantime, many details must be worked out before patients can be safely and effectively treated with these new products.
Read Article

Page 4 of 4

Stay In The Know

Stay up to date on the matters of value in cancer by signing up for the free, bi-monthly VBCC print publication and VBCC weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.